Prescreening Study to Identify Potential Participants With ABCA4-related Retinopathy for ACDN-01 Clinical Trials
Status: Recruiting
Location: See all (8) locations...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY
This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 5
Healthy Volunteers: f
View:
• Presence of mutations in the ABCA4 gene
• ABCA4 retinopathy phenotype (Stargardt disease type 1 or cone-rod dystrophy)
Locations
United States
California
University of San Francisco
RECRUITING
San Francisco
Florida
Vitreo Retinal Associates
RECRUITING
Gainesville
Massachusetts
Massachusetts Eye and Ear
RECRUITING
Boston
Maryland
Wilmer Eye Institute at John Hopkins
RECRUITING
Baltimore
Michigan
University of Michigan Kellogg Eye Center
RECRUITING
Ann Arbor
Ohio
Cincinnati Eye Institute
RECRUITING
Cincinnati
Texas
Retina Foundation of Texas
RECRUITING
Dallas
Retina Consultants of Texas
RECRUITING
Houston
Contact Information
Primary
Associate Director, Clinical Operations
researchtrials@ascidian-tx.com
207-573-0412
Time Frame
Start Date: 2024-06-20
Estimated Completion Date: 2030-08-31
Participants
Target number of participants: 50
Treatments
Prescreening Group
The prescreening study consists of genetic and visual assessments and will require at least 1 onsite visit. All clinical assessments performed are for the purpose of determining research eligibility for ACDN-01 clinical trials.
Related Therapeutic Areas
Sponsors
Leads: Ascidian Therapeutics, Inc